TAO Synergies TAOX
NASDAQ TAOX
$4.12 +0.11 (+2.72%)
As of: Sep 9, 2026 · 2:01 PM EDT

TAO Synergies (TAOX) Common Equity (2019 - 2026)

TAO Synergies' (TAOX) quarterly Common Equity came in at $12.7 million in Q2 2026, down 26.09% on a YoY basis from $17.2 million in Q2 2025, and down 45.18% quarter-over-quarter from $23.3 million in Q1 2026.

Analysis

TAO Synergies (TAOX) Common Equity (2019 - 2026) Analysis & Trends

TAO Synergies (TAOX) has reported Common Equity for 8 consecutive years, with $12.7 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Common Equity fell 26.09% year-over-year to $12.7 million; the trailing twelve-month figure through Jun 2026 stood at $12.7 million (down 26.09% YoY), and the FY2025 full-year result was $21.1 million, up 259.01% from the prior year.
  • Common Equity eased to $12.7 million in Q2 2026 per TAOX's latest filing, from $23.3 million in the prior quarter.
  • Across five years, Common Equity topped out at $32.7 million in Q4 2022 and bottomed at $5.2 million in Q1 2025.
  • Historically, Common Equity has averaged $21.2 million across 5 years, with a median of $22.7 million in 2024.
  • The sharpest annual moves came in 2025 and 2026: Common Equity plunged 76.56% in 2025, then soared 349.98% in 2026.
  • Over 5 years, Common Equity stood at $32.7 million in 2022, then retreated by 25.53% to $24.3 million in 2023, then tumbled by 75.92% to $5.9 million in 2024, then jumped by 259.01% to $21.1 million in 2025, then plunged by 39.44% to $12.7 million in 2026.
  • According to Business Quant data, Common Equity over the past three periods registered $12.7 million, $23.3 million, and $21.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Amgen 210.98 Bn 196.99 Bn 7.24 Bn 11.69 Bn
2 Gilead Sciences 181.24 Bn 178.06 Bn 6.22 Bn 11.83 Bn
3 Vertex Pharmaceuticals 132.38 Bn 124.53 Bn 2.84 Bn 20.25 Bn
4 Regeneron Pharmaceuticals 82.97 Bn 74.97 Bn 3.93 Bn 31.71 Bn
5 Argenx Se 61.59 Bn 56.41 Bn 1.37 Bn 8.42 Bn
6 Moderna 54.80 Bn 49.67 Bn 52.00 Mn 6.76 Bn
7 Alnylam Pharmaceuticals 34.09 Bn 30.78 Bn 992.69 Mn 1.35 Bn
8 Biogen 31.34 Bn 30.05 Bn 1.96 Bn 18.85 Bn
9 Roivant Sciences 30.11 Bn 30.11 Bn 1.16 Mn 4.92 Bn
10 TAO Synergies 30.79 Mn 30.79 Mn - 12.75 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 12.75 Mn
Mar 31, 2026 23.26 Mn
Dec 31, 2025 21.05 Mn
Sep 30, 2025 16.07 Mn
Jun 30, 2025 17.25 Mn
Mar 31, 2025 5.17 Mn
Dec 31, 2024 5.86 Mn
Sep 30, 2024 12.80 Mn
Jun 30, 2024 18.80 Mn
Mar 31, 2024 22.05 Mn
Dec 31, 2023 24.35 Mn
Sep 30, 2023 26.74 Mn
Jun 30, 2023 24.83 Mn
Mar 31, 2023 31.46 Mn
Dec 31, 2022 32.69 Mn
Sep 30, 2022 26.67 Mn
Jun 30, 2022 28.95 Mn
Mar 31, 2022 31.68 Mn
Dec 31, 2021 33.53 Mn
Sep 30, 2021 31.35 Mn